



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Steven C. Quay

Serial No.: 09/678,591

Filing Date: October 3, 2000

For: LONG-ACTING OXYTOCIN ANALOGUES FOR THE TREATMENT AND PREVENTION OF BREAST CANCER AND PSYCHIATRIC DISORDERS

RECEIVED

APR 01 2002

TECH CENTER 1600/2900


Group Art Unit: 1614

Examiner: Dwayne C. Jones

DATE OF DEPOSIT: March 18, 2002

I HEREBY CERTIFY THAT THIS PAPER IS BEING  
 DEPOSITED WITH THE UNITED STATES POSTAL SERVICE  
 AS FIRST CLASS MAIL, POSTAGE PREPAID ON THE DATE  
 INDICATED ABOVE AND IS ADDRESSED TO THE  
 ASSISTANT COMMISSIONER FOR PATENTS,  
 WASHINGTON, DC 20231.

TYPED NAME: JEFFREY L KING  
 REGISTRATION NO. 38,515



Box  NON-FEE  
 AF

Commissioner for Patents  
 Washington DC 20231

Sir:

## AMENDMENT TRANSMITTAL LETTER

Transmitted herewith for filing in the above-identified patent application is:

- A Preliminary Amendment.
- An Amendment Responsive to the Office Action Dated December 18, 2001.
- An Amendment Supplemental to the Paper filed \_\_\_\_\_.
- Other: \_\_\_\_\_.
- Applicant(s) has previously claimed small entity status under 37 CFR §1.27.

Applicant(s) by its/their undersigned attorney, claims small entity status under 37 CFR §1.27 as:

- an Independent Inventor
- a Small Business Concern
- a Nonprofit Organization

- This application is no longer entitled to small entity status. It is requested that this be noted in the files of the Patent and Trademark Office.
- Substitute Pages \_\_\_\_\_ of the Specification are enclosed.
- An Abstract is enclosed.
- \_\_\_\_\_ Sheets of Proposed Corrected Drawings are enclosed.
- A Certified Copy of each of the following applications: is enclosed.
- An Associate Power of Attorney is enclosed.
- Information Disclosure Statement.
  - Attached Form 1449.
  - A copy of each reference as listed on the attached Form PTO-1449 is enclosed herewith.
- Appended Material as follows: \_\_\_\_\_.
- Other Material as follows: Copies of the March 26, 2001 Information Disclosure Statement, Transmittal Form, Form PTO-1449, and return receipt postcard.

## FEE CALCULATION

- No Additional Fee is Due.


	REMAINING AFTER AMENDMENT	HIGHEST PAID FOR	EXTRA	SMALL ENTITY		NOT SMALL ENTITY	
				RATE	Fee	RATE	Fee
TOTAL CLAIMS	50	38 (20 MINIMUM)	12	\$9 EACH	\$108.00	\$18 EACH	\$
INDEP. CLAIMS	6	5 (3 MINIMUM)	1	\$42 EACH	\$42.00	\$84 EACH	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT				\$140	\$	\$280	\$
<input type="checkbox"/> ONE MONTH EXTENSION OF TIME				\$55	\$	\$110	\$
<input type="checkbox"/> TWO MONTH EXTENSION OF TIME				\$200	\$	\$400	\$
<input type="checkbox"/> THREE MONTH EXTENSION OF TIME				\$460	\$	\$920	\$
<input type="checkbox"/> FOUR MONTH EXTENSION OF TIME				\$720	\$	\$1440	\$
<input type="checkbox"/> FIVE MONTH EXTENSION OF TIME				\$980	\$	\$1960	\$
<input type="checkbox"/> LESS ANY EXTENSION FEE ALREADY PAID				minus	(\$ )	minus	(\$ )
<input type="checkbox"/> TERMINAL DISCLAIMER				\$55	\$	\$110	\$
<input type="checkbox"/> OTHER FEE OR SURCHARGE AS FOLLOWS:							
TOTAL FEE DUE					\$150.00		\$

- A Check is Enclosed in the Foregoing Amount Due.
- Petition is hereby made under 37 C.F.R. 1.136(a) to extend the time for response to the Office Action of \_\_ to and through \_\_ comprising an extension of the shortened statutory period of \_\_ month(s).
- The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to deposit account 23-3050. This sheet is provided in duplicate.
- The Commissioner is authorized to charge payment of the following fees and to refund any overpayment associated with this communication or during the pendency of this application to deposit account 23-3050. This sheet is provided in duplicate.

- The Foregoing Amount Due for Filing this Paper.
- Any additional filing fees required, including fees for the presentation of extra claims under 37 C.F.R. 1.16.
- Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d).


**SHOULD ANY DEFICIENCIES APPEAR** with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the United States Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: March 18, 2002



Jeffrey J. King  
Registration No. 38,515

Woodcock Washburn LLP  
One Liberty Place - 46th Floor  
Philadelphia PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439      © 2001 WW



DOCKET NO.: ATC-0035

COPY OF PAPERS  
ORIGINALLY FILED

PATENT

#8A  
n.n.  
4/10/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In Re Application of:

Steven C. Quay

Serial No.: 09/678,591

Group Art Unit: 1614

Filing Date: October 3, 2000

Examiner: Dwayne C. Jones

For: LONG-ACTING OXYTOCIN ANALOGUES FOR THE TREATMENT AND  
PREVENTION OF BREAST CANCER AND PSYCHIATRIC DISORDERS

DATE OF DEPOSIT: March 18, 2002  
I HEREBY CERTIFY THAT THIS PAPER IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS FIRST CLASS MAIL, POSTAGE  
PREPAID ON THE DATE INDICATED ABOVE  
AND IS ADDRESSED TO THE COMMISSIONER  
FOR PATENTS AND TRADEMARKS,  
WASHINGTON, DC 20231.

TYPED NAME: Jeffrey A. King  
REGISTRATION NO.: 38,515

Commissioner for Patents  
Washington, DC 20231

Sir:

**AMENDMENT**

In response to the Office Action dated December 18, 2001, entry and  
consideration of the following amendments and remarks is earnestly requested.

**IN THE CLAIMS:**

Please add new claims 39-50 as follows:

A1  
--39. (New) A method for treatment of breast cancer in a mammalian patient comprising administering to said patient a therapeutically effective amount of one or more compound(s) selected from the group consisting of carbetocin and other long-acting oxytocin analogues in a pharmaceutically acceptable carrier sufficient to inhibit growth of breast cancer in said patient.

40. (New) The method of claim 39, wherein said one or more oxytocin analogue(s) comprises carbetocin.

03/28/2002 SESHE1 00000115 09678591  
01 FC:2203  
02 FC:2202